Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, speaks on how capabilities of cognitive behavioral therapy have evolved to a more user-friendly approach in the management of chronic insomnia.
With cognitive behavioral therapy (CBT) now accessible through smartphones, its evolution to a more user-friendly approach now provides access to effective treatments for chronic insomnia across populations nationwide, said Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy.
Transcript
How have the capabilities of digital CBT evolved and how has this influenced patient outcomes?
The capabilities of digital CBT evolved by having more access and more user-friendly programs and applications. So, many people these days, even underserved patient populations, all sorts of patient populations, have access to a smartphone and are able to get WiFi, whether it be in public spaces, coffee shops, things like that, and they're able to charge their phone in these same settings.
So, the capabilities–the first capability of digital CBTi [CBT for insomnia] is that the access has been expanded where so many people have access to it. The capabilities have also improved by the technology becoming a little more user-friendly, and a little more streamlined. So, some of the early CBTi apps or CBTI programs were a little bit clunky, hard to get from tab to tab, section to section, and it led to not a rewarding user experience, which could contribute to people kind of giving up on the app or the program and maybe looking for other treatments.
But the capabilities have really improved by making these apps more user-friendly. So they're just easier, simpler, more direct to use–so you're not switching all over the place. And with many people, even like I was saying, underserved people having access to smartphones, it's really come together nicely where digital CBT apps are accessible and can be used.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More